Tools

Más de 5.000 receptores del SSB dieron el so consentimientu pa cobrar l'IMV

Los conceyos asturianos yá recabaron el consentimientu de más de 5.000 perceptores de l'ayuda autonómica salariu social básicu (SSB), qu'otorga'l Principáu, pa pasar a cobrar l'ingresu mínimu vital (IMV), que ye competencia estatal.
Load more
Read full article on: europapress.es
Petri Dishes with Alexandra Petri (Oct. 27)
Humor columnist Alexandra Petri takes your questions on the news and political in(s)anity of the day.
1m
washingtonpost.com
Polish President Tests Positive For The Coronavirus
President Andrzej Duda, who says he's experiencing no symptoms, will self-isolate. Duda has apologized to those he came into contact with, who will also need to go into quarantine.
npr.org
Sen. Kelly Loeffler tests negative for COVID-19 after two staffers infected, will vote to confirm ACB
Sen. Kelly Loeffler tested negative for COVID-19 on Saturday, just a day after two staffers learned they were infected.
foxnews.com
Shock Poll: Donald Trump Down One Point Among Black Voters in Battleground Michigan
The time and resources President Trump's campaign has been pouring into the battleground state of Michigan appear to be paying off, according to two new polls.
breitbart.com
Arcadia, a WWII incarceration site, names its first police chief of Japanese descent
Arcadia announced that 28-year veteran Capt. Roy Nakamura will officially take over as head of the police department Jan. 9
latimes.com
President Trump Casts Vote in Florida Ahead of Rallies
Trump could have mailed in his ballot, but opted to vote in person at a public library. He was greeted by cheering crowds
time.com
Video shows aftermath of Navy aircraft's crash in neighborhood
The crew of a Navy T-6B Texan II was killed when the two-seat airplane crashed in a small town near Mobile, Alabama, according to the Navy. CNN affiliate WPMI has reports.
edition.cnn.com
Trump to deliver remarks in North Carolina on jam-packed Saturday
President Trump has arrived in the critical swing state of North Carolina, the second of a total of five stops the commander-in-chief will make on Saturday in the final sprint to the Nov. 3 election.
foxnews.com
U.S. Navy training plane crashes in Alabama, killing 2
The T-6B Texan II training plane crashed Friday in an Alabama residential neighborhood near the Gulf Coast.
cbsnews.com
UFC 254 video: Miranda Maverick wins after wicked elbow slices open bridge of Liana Jojua's nose
A perfectly placed elbow changed the trajectory of Miranda Maverick vs. Liana Jojua in a split second.        Related StoriesUFC 254 video: Miranda Maverick wins after wicked elbow slices open bridge of Liana Jojua's nose - EnclosureUFC 254 discussion threadUFC 254 play-by-play and live results (11 a.m. ET) 
usatoday.com
Jennifer Aniston discourages voters from supporting Kanye West, casts her ballot for Joe Biden
Jennifer Aniston officially voted in the 2020 presidential election. In addition to revealing who she voted for, she also discouraged voters from supporting Kanye West.
foxnews.com
Native voters struggle amid growing reliance on mail-in voting
washingtonpost.com
Jerry Jeff Walker, country music legend and 'Mr. Bojangles' songwriter, dies at 78
Jerry Jeff Walker, a country singer-songwriter known for penning the hit "Mr. Bojangles," has died. He was 78.
foxnews.com
Hilary Duff is pregnant, expecting baby No. 3 with Matthew Koma
Hilary Duff is pregnant with baby number three!
nypost.com
‘The Vow’ & ‘Seduced’ Subject Keith Raniere Speaks Out In Rare First Interview Since Arrest
The NXIVM founder discusses how ‘the devil’ and ‘a saint’ should get the same treatment by the justice system.
nypost.com
We need to burn the Affordable Care Act and rebuild it piece by piece
The Supreme Court probably is not going to nullify ObamaCare. Congress should — one piece at a time. Democrats opposed to the nomination of Amy Coney Barrett to the Supreme Court were very worried — or at least pretended to be worried — about the upcoming case challenging the constitutionality of the so-called Affordable Care...
nypost.com
"The Price is Right" is returning with no live audience
Network television's number-one-rated daytime series is firing back up with new safety protocols in place.
cbsnews.com
Kevin Hart is ready for the revived MDA telethon
For Kevin Hart, it's all about the kids.
edition.cnn.com
Trump calls Sacha Baron Cohen 'a creep' after 'Borat' clip shows actress entering White House
President Donald Trump called Sacha Baron Cohen "a creep" after previously unseen footage from "Borat 2" was shared to Twitter Friday.        
usatoday.com
Jimmy Kimmel shares son's struggles, urges people to vote
Comedian Jimmy Kimmel and wife Molly McNearney shared a video of three-year-old son's health struggles in hopes of inspiring people to vote.       
usatoday.com
How a Holocaust survivor helped me find love — and hope during the pandemic
Lately, I’ve been thinking about hope. Because I’m fresh out. The ills of humanity — turmoil, strife, jealousy, hatred, sickness and death — have flown out of Pandora’s box all at once, it seems. Hope, “The thing with feathers,” as Emily Dickenson wrote, that “perches in the soul,” is the only thing that remains within....
nypost.com
Kelly Ripa talks hubby Marc Consuelos’ penis size after pic impresses fans
Ripa confirmed that the "Riverdale" actor is blessed below the belt after fans were taken aback by a photo highlighting his "package."
nypost.com
Atlanta man wins $50G FOX Bet Super 6 Debate Game jackpot
An Atlanta man won the $50,000 jackpot from the FOX Bet Super 6 Debate Game.
foxnews.com
Florida deputies say arsonist wearing trash bags torched a dozen garbage trucks
A Florida arsonist was wearing goggles and black garbage bags when he torched a dozen commercial garbage trucks worth more than $3 million.
foxnews.com
Brooklyn man charged with reckless driving, crashing into cop car
A Brooklyn man slammed into a cop car during a wild episode after he sped away from a traffic stop, police said. Samson Alabi, 29, was nabbed for speeding and running red lights around 12:30 a.m. in Canarsie when cops pulled his blue 2020 Nissan Armada over at Kingston and East New York avenues. That’s...
nypost.com
Motorcyclist dies following collision in Colesville area
Christian Richardson died at a hospital from injuries sustained in the crash.
washingtonpost.com
Animal rights activist charged with deceptive advertising, treating pets without license
A Hollywood-backed animal rights activist was charged last week with practicing veterinary medicine without a license and deceptive advertising for products he hawked at his pet food stores. Los Angeles prosecutors filed the charges against Marc Ching after a Los Angeles Times investigation unearthed years of complaints by veterinarians, who said Ching had encouraged pet...
1 h
nypost.com
WWE 'Hell in a Cell' 2020: Start Time, Card and How to Watch Online
Otis will put his MITB briefcase on the line this Sunday.
1 h
newsweek.com
The 100 Best 'SNL' Episodes of All Time
'Saturday Night Live' has been on the air for more than four decades and even through the COVID-19 pandemic, produced episodes to keep their audience laughing. Here's a look back at the 100 best 'SNL' episodes of all time.
1 h
newsweek.com
Trump Jr. floats 2024 run for president: ‘This will make the lib heads explode’
Trump 2024? Donald Trump Jr. posted a photo to Instagram Saturday standing in front of a “Don Jr 2024” sign, teasing that prospect. “Hahahahaha. Oh boy. This was a sign I saw up at the Fallon Nevada Livestock Auction. This will make the lib heads explode. To whomever made that thanks for the compliment… but...
1 h
nypost.com
Trump Votes Early In Florida, Says He Voted 'For A Guy Named Trump'
The president cast his ballot from his adopted home state before departing for rallies on Saturday in North Carolina, Ohio and Wisconsin. More than 50 million Americans have already voted early.
1 h
npr.org
Two-Thirds of Trump Supporters Won't Put Up Yard Signs Over Vandalism Concerns
Forty-five percent of Trump supporters also won't talk to friends or co-workers about their support for the president's re-election out of alienation concerns.
1 h
newsweek.com
Senate to convene rare Saturday session to debate Amy Coney Barrett nomination
The Senate will gavel in a rare Saturday session this afternoon to debate confirming Judge Amy Coney Barrett to the Supreme Court -- just days before voters decide whether Republicans will maintain control of the Senate and the White House.
1 h
foxnews.com
Pennsylvania Supreme Court rules mail-in ballots can’t be rejected over mismatched signatures
A voter in Philadelphia returns their mail-in ballot. | Mark Makela/Getty Images It’s a blow for Republicans who challenged the state’s guidance that different-looking signatures shouldn’t be disqualifying. The Pennsylvania Supreme Court ruled unanimously on Friday that mail-in ballots cannot be rejected if a voter’s signature looks different than the one on their registration form. The ruling came after Pennsylvania’s Democratic Secretary of State Kathy Boockvar, the state’s top election official, turned to the court for clarity on the legality of her signature-matching policy. She introduced guidance in September that said ballots shouldn’t be thrown out due to mismatched signatures, and has since been mired in a legal battle with President Donald Trump’s reelection campaign and other Republicans. The court decision — backed by five Democrat and two Republican justices — marks a victory for Democrats and voting-rights advocates in a critical battleground state Trump won by roughly 44,000 votes in 2016. It comes on the heels of another loss for Republicans in the state: the October 19 order by the US Supreme Court, which let stand a Pennsylvania Supreme Court ruling that mailed-in ballots received up to three days after Election Day must be counted. “County boards of elections are prohibited from rejecting absentee or mail-in ballots based on signature comparison conducted by county election officials or employees, or as the result of third-party challenges based on signature analysis and comparisons,” the court wrote, upholding Boockvar’s guidance. “If the Voter’s Declaration on the return envelope is signed and the county board is satisfied that the declaration is sufficient, the mail-in or absentee ballot should be approved for canvassing unless challenged in accordance with the Pennsylvania Election Code,” Boockvar wrote in September. “The Pennsylvania Election Code does not authorize the county board of elections to set aside returned absentee or mail-in ballots based solely on signature analysis by the county board of elections.” Over 1.4 million Pennsylvanians have already submitted mail ballots, according to the US Elections Project, the overwhelming majority of which have been sent by registered Democrats. Pennsylvania and other states across the US are expecting an unprecedented surge in mail ballots as voters attempt to find ways to avoid in-person voting due to the coronavirus pandemic. Signature-matching processes are a contentious issue because, as political scientists and voting rights advocates point out, election officials who are likely to reject far more authentic signatures than false ones in an electoral system in which fraud is exceedingly rare. As The Atlantic reported, a Carroll College political scientist working on behalf of plaintiffs challenging a signature-matching law in Ohio calculated that there was a 97 percent chance that a given ballot in Ohio rejected on the basis of a signature mismatch was wrongly rejected. And in 2016, perceived signature mismatches constituted the biggest reason mail ballots were disqualified. Voting rights advocates have also pointed out that signature matching processes are likely to disproportionately exclude authentic signatures from very young voters, very old voters, disabled voters, and voters of color. In battleground states — like Pennsylvania — with potentially razor thin margins between candidates, policies surrounding matching signatures could play a decisive role in the outcome of the election. With a significant 20 electoral votes at stake, and an ideologically heterogeneous population, Pennsylvania’s laws on including ballots are particularly pivotal. According to FiveThirtyEight’s polling averages, Democratic nominee Joe Biden holds a 6 point lead in the polls over Trump in Pennsylvania — but both candidates have made the state a focus in the final days ahead of the election, hoping to win over new supporters. Will you help keep Vox free for all? The United States is in the middle of one of the most consequential presidential elections of our lifetimes. It’s essential that all Americans are able to access clear, concise information on what the outcome of the election could mean for their lives, and the lives of their families and communities. That is our mission at Vox. But our distinctive brand of explanatory journalism takes resources. Even when the economy and the news advertising market recovers, your support will be a critical part of sustaining our resource-intensive work. If you have already contributed, thank you. If you haven’t, please consider helping everyone understand this presidential election: Contribute today from as little as $3.
1 h
vox.com
US in upward trajectory of new COVID-19 cases: HHS memo
Forty-two states and territories are in an upward trajectory of new COVID-19 cases, while only nine jurisdictions are improving.
1 h
abcnews.go.com
Arizona Poll: Donald Trump 47%, Joe Biden 46%
Joe Biden and President Trump are statistically tied in Arizona, two surveys examining the presidential race in the Grand Canyon State reveal.
1 h
breitbart.com
Security company that sought Special Forces to guard Minnesota polls agrees to stay out of state, AG says
Minnesota Attorney General Keith Ellison warned that a plan by Atlas Aegis to send former military personnel to polling sites in the state would amount to voter intimidation.
1 h
washingtonpost.com
Long Lines as New Yorkers Flood Polling Places for Early Voting
At Madison Square Garden, Barclays Center and other sites, people arrived hours before polls opened. This is the first time that early voting has been allowed in New York in a presidential election.
1 h
nytimes.com
Arnold Schwarzenegger says he feels 'fantastic' after undergoing heart surgery
The 73-year-old actor and former Republican governor of California revealed on social media Thursday that he had his aortic valve replaced.
1 h
edition.cnn.com
Arnold Schwarzenegger says he feels 'fantastic' after undergoing heart surgery
He may be known as a robot assassin. But in real life, he's only human.
1 h
edition.cnn.com
Deadly Colorado wildfire tears through Rocky Mountain National Park, threatens Estes Park
Colorado's second-largest wildfire on record is expanding Saturday before an expected snowstorm.
1 h
washingtonpost.com
Fox Business Host Lou Dobbs Tells South Carolina Residents to Vote Against Lindsey Graham
"I don't know why anyone in the great state of South Carolina would ever vote for Lindsey Graham."
1 h
newsweek.com
Stream It Or Skip It: ‘Totally Under Control’ on Hulu, Alex Gibney’s Unvarnished Rewind Of The Last Ten Months
The manifold failures of the Trump administration's pandemic response are put in sobering perspective by Alex Gibney's Totally Under Control. This doc isn't ripped from the 2020 headlines -- it is made of them.
2 h
nypost.com
What the next GDP figure will — and won’t — mean
A trader works on the floor of the New York Stock Exchange on March 18, 2020. The economy is still recovering from a catastrophic spring. | Xinhua via Getty Images Economic data will likely show record-breaking growth. But the economy hasn’t recovered. Five days before Election Day, new data will be released providing the first look at how fast the economy grew in the third quarter of 2020. It’s a safe bet that third-quarter growth will clock in at the fastest pace ever recorded. It’s also a safe bet that the number will be ballyhooed as a great accomplishment. Maybe the greatest ever. But in reality, the job of rebuilding the economy will be far from done. Most economic forecasters expect the GDP growth figure announced on October 29 to be somewhere in the neighborhood of 25 to 30 percent at an annual rate; some think it could even come in a few percentage points higher than that. If the number is somewhere in that range, it will indeed earn the title of the fastest GDP growth figure ever posted. And it will signify that the country has made some progress on the road to recovery. But it will not mean the economy is booming, or even that it has fully recovered. In fact, the third-quarter increase will represent only a partial rebound from another record-setter: the sharpest collapse ever recorded during the second quarter. The truth is that the recovery is far from complete; momentum has slowed in the past few months; and risks to further progress abound. Even record-breaking growth won’t be enough to undo what happened this spring During the spring quarter, there was a colossal drop in real GDP—more than 31 percent at an annual rate. That drop resulted from the imperative to put the economy into a temporary deep-freeze, in hopes of slowing the spread of the virus. The shape of this recession differed dramatically from any other in living memory. In the typical post-World-War-II recession, manufacturing and construction have been hit especially hard. This time, it was service industries that took it on the chin—especially ones that depend on lots of people being close together. Think bars, restaurants, air travel, hotels, conventions, and the like. The second-quarter decline was triple the size of the previous worst-ever quarterly drop since the current method of score-keeping began in 1947. A couple of quarters during the Great Depression and during the decommissioning from World War II were probably worse, but when you need to reach back to the ‘30s and ‘40s for comparisons, you begin to get the idea for how bad the second quarter of this year was. In fact, the decline was so bad that even the record-breaking growth we’re likely to see announced for the third quarter won’t be enough to reverse it. As shown in the chart, even if the late-October announcement comes in at 33 percent—toward the more optimistic end of the range, and in line with the expectation of the economic forecasting firm IHS Markit—real GDP will remain 3½ percent below its previous peak, reached at the end of last year. And it will remain a little more than 5 percent below where it would have been if growth had continued steadily, uninterrupted by the pandemic, at the average pace of 2018 and 2019. Real GDP would have to have increased a whopping 53 percent at an annual rate in the third quarter to return to its previous level. (Why not 36.4 percent, if GDP declined at a 5 percent annual rate in the first quarter, and a further 31.4 percent rate in the second quarter? Because that’s not how it works. Suppose GDP was at 100, and then it fell to 50 — a drop of 50 percent. If it then rose by 50 percent, it would only move back to 75. A similar calculation is required here.) The recovery has slowed Most of the rebound reflected in the GDP growth figure that will be published at the end of October actually occurred in May and June — before the third quarter even began. IHS Markit constructs estimates of monthly GDP using methodology that mimics as closely as possible the procedures underlying the official quarterly numbers published by the Commerce Department. According to their estimates, real GDP rebounded about 5 percent in May and 6 percent in June. After that, though, monthly growth slowed sharply, to 1½ percent in July and ½ percent in August. If their estimates prove accurate, a 33 percent GDP growth rate for the third quarter would be consistent with essentially no growth in the month of September. Sound crazy? Plenty of other indicators suggest that momentum has slowed. In May and June, the pace of household spending rebounded quickly following a breathtaking collapse in the preceding two months. But in July and August, the improvement slowed to a crawl. Job growth has slowed as well. By September, employment had recovered only about half the losses sustained in March and April. Even if the September pace of job recovery is maintained, the previous peak level of employment will not have been reattained until January 2022. The unemployment rate in September—the latest figure currently available—was 7.9 percent. That was down from a peak of 14.7 percent in April, but still more than twice the 3.5 percent rate in February, just before the roof fell in. Why has the momentum of recovery slowed? One likely contributing factor is that the easy part has already been done. Once the initial lockdown was lifted, many employers were still financially viable, and their lines of business didn’t depend on bringing together large numbers of people, so they could bring more workers back on board. But others were not so fortunate. For them, the current situation has begun to look more like a classic recession. A second likely contributing factor is that with each passing day, more and more families have run out of spending power: The $600 supplement to weekly unemployment insurance benefits provided under the CARES Act expired at the end of July; the relief payments of $1,200 per adult and $500 per child have not been not renewed; and the aid provided to small businesses under the Paycheck Protection Program has in many cases run dry. Unfortunately, there’s ample cause for concern that the recovery may continue to stall. The virus remains out of control. No one knows for sure when a safe and effective vaccine will be widely available, but everyone agrees that it will be difficult to build a durable and complete economic recovery until one is. Somehow, not all hope for a near-term fiscal agreement has been snuffed out, and one may yet be struck before November 3. But another possibility is that Congressional action will have to await a lame-duck session late this year, or even be postponed until the new Congress is seated in 2021. Amid all the conflicting interpretations that you will hear over the next few weeks, what we know is this: The economy has taken a step toward recovery since the bottom fell out in April. But the job is nowhere near complete; if you need convincing on that point, just ask the millions of people who remain jobless or the millions who report being food-insecure. The big number for GDP growth during the July-September period will represent a step back toward normal, but it will be no cause for unfurling another “Mission Accomplished Banner.” Unfortunately, there is still a long way to go yet in putting back together any semblance of a robust economy. Congress can help in that process by passing another fiscal support bill. David Wilcox is a nonresident senior fellow at the Peterson Institute for International Economics and the former director of the Division of Research and Statistics at the Federal Reserve Board.
2 h
vox.com
The FDA approved remdesivir to treat Covid-19. Scientists are questioning the evidence.
The Food and Drug Administration granted full approval to remdesivir for Covid-19 treatment. It’s the first drug to receive this designation. | Fadel Dawood/Picture Alliance via Getty Images Researchers are concerned the FDA’s first full approval of a Covid-19 drug doesn’t have enough research behind it. The Food and Drug Administration on Thursday gave itsfirst full approval for a drug to treat Covid-19 to the antiviral remdesivir. But some researchers say the FDA is once again promoting a Covid-19 therapy based on shaky evidence. Developed by Gilead Sciences and marketed under the brand name Veklury, remdesivir previously received emergency use authorization from the FDA in May, which allowed it to be used to treat patients with severe Covid-19. In August, the FDA relaxed its guidelines to allow the drug to be used in less serious cases. President Donald Trump also took the drug as part of his treatment when he was diagnosed with Covid-19 earlier in October. Full FDA approval promotes remdesivir to the standard of care for hospitalized patients, and other potential treatments for Covid-19 will now have to be compared to it during clinical research. “Today’s approval is supported by data from multiple clinical trials that the agency has rigorously assessed and represents an important scientific milestone in the Covid-19 pandemic,” FDA commissioner Stephen Hahn in a statement Thursday. The FDA based its decision on three randomized controlled trials. (The largest of those looked at 1,062 hospitalized patients.) The trials’ results showed that remdesivir reduced the length of hospital stays in some Covid-19 patients. However, shortly before the approval was granted, a study from the World Health Organization announced preliminary results that found the drug had no effect on mortality and — unlike the FDA’s findings — negligible effects on how long patients were in hospitals. The study, known as the Solidarity Trial, recruited almost 12,000 patients, making it the largest Covid-19 treatment study in the world thus far. Researchers say the findings should have given the FDA pause. “I think it’s really inappropriate to give this a full approval because the data don’t support it,” said Eric Topol, a professor of molecular medicine at the Scripps Research Translational Institute. “What [the FDA] should have done instead of issuing the approval was put on the brakes.” Absent a vaccine, doctors are desperate for an effective treatment for Covid-19, and the FDA’s approval of remdesivir finally gives them an option. In the United States, Covid-19 case counts are rising again, with states like Wisconsin opening field hospitals to deal with a looming surge. But the approval of remdesivir has raised concerns, not only because of the results of the WHO’s trial but also because it follows a number of questionable FDA authorizations for other Covid-19 therapies that appear to have been influenced by political pressure from the White House. Now some researchers and doctors are concerned that remdesivir could not only be less effective than promised, but that its approval could also undermine other efforts to develop better Covid-19 therapies. How remdesivir works against Covid-19 — and why its effects are limited Remdesivir seems to be most effective relatively early on for hospitalized patients with severe Covid-19. To help beat back the illness, it interferes with how SARS-CoV-2, the virus that causes Covid-19, makes copies of itself. The virus uses genetic instructions in the form of RNA, written in a code made of molecules represented by the letters A, U, G, and C. The drug mimics the molecule represented by A, adenosine. The fake adenosine blocks the virus from copying itself but doesn’t fool human cells. The result is the virus can’t reproduce as much within a patient’s body. The antiviral drug was originally developed to treat the Ebola virus, and it hasreceived a hefty investment from the US government over almost two decades, as Ekaterina Cleary, lead data analyst and research associate at the Center for Integration of Science and Industry, wrote in a piece for Stat News: Research from the Center for Integration of Science and Industry, with which I am affiliated, determined that between gathering knowledge behind remdesivir’s chemical structure and molecular target, the NIH invested as much as $6.5 billion between 2000 and 2019. Remdesivir treatment is not without risks. It has been shown to cause some side effects in some people, such as elevated liver enzymes, which could indicate liver damage. The drug can also trigger allergic reactions, resulting in fever, shortness of breath, wheezing, swelling, low blood oxygen, and changes in blood pressure. For a patient with private insurance, the intravenous drug can cost $3,120 for a five-day course of treatment. Antivirals like remdesivir are most effective early on during the progression of Covid-19, when most of the damage is being done by the virus itself. It’s less effective in later stages, when the problem isn’t just the virus. “The severe manifestations of the disease are caused by an out-of-control immune response to the infection,” said Angela Rasmussen, a virologist at the Columbia University Mailman School of Public Health. Liu Guanguan/China News Service via Getty Images Gilead Sciences initially developed the antiviral drug remdesivir to treat the Ebola virus. If the immune system gets riled up, it can cause a lot more destruction than SARS-CoV-2 and require more drastic interventions like intubation, at which point another approach is needed. That’s a big reason why corticosteroids like dexamethasone, which tamp down on the immune system, are the only drugs so far reliably demonstrated to actually reduce mortality from Covid-19. But giving a patient steroids too early in an infection could prevent the immune system from mounting an effective response against SARS-CoV-2. Coming up with an effective treatment regimen for Covid-19 requires delicately balancing where a patient is in the course of their infection and how severe their illness has become. But given how murky it is to identify a Covid-19 infection to begin with, let alone confirming the diagnosis and starting the correct treatment during the appropriate window, researchers have a hard time teasing out what interventions work best. That’s why carefully controlled large-scale clinical trials are so important. And with mixed results coming from the studies conducted to date, some scientists don’t think the evidence produced for remdesivir’s effectiveness is enough for the FDA to grant approval. “I was really surprised when I saw that news,” Rasmussen said. The approval of remdesivir may actually complicate research and treatment of Covid-19 The FDA has already made some controversial decisions around drugs to treat Covid-19. In March, the agency granted an emergency use authorization for the anti-malaria drug hydroxychloroquine after President Trump called it a “game changer.” Then in June, FDA revoked the EUA, saying hydroxychloroquine was “unlikely to be effective” and could cause lead to heart problems. Then in August, the agency granted an EUA for convalescent plasma to treat Covid-19. But the National Institutes of Health said that the evidence the FDA used was “insufficient.” There is more evidence that remdesivir works, but that’s not saying much. “It’s not as weak as the case for plasma, but that’s no standard. The case for plasma is nonexistent,” said Jeremy Faust, an attending physician in the Brigham and Women’s Hospital and an instructor at Harvard Medical School. “There is actually randomized controlled trial data that suggests for a subset of patients remdesivir can decrease hospital length of stay.” The strongest results in favor of remdesivir show that the patients who received it had a median recovery time of 10 days compared to 15 days for those who took the placebo. It’s a significant effect, but it’s not huge, and it’s certainly not a cure for Covid-19 — or a way to guarantee fewer deaths. Faust said that one of his concerns with this new FDA approval is a phenomenon known as indication creep, where a treatment that is shown to work in only a limited set of circumstances gets prescribed to more and more people. In this case, the worry is remdesivir, which is approved only for Covid-19 patients over 12 years old who needed to be hospitalized, could start being used in patients with milder courses of the illness, or used in more severe cases of the disease past the point where it could be effective. “What will happen, I guarantee, is people will start to use the medication more than they need it,” Faust said. And since the course of treatment is five days, it could extend the length of hospital stays in patients who would otherwise have remained for a shorter duration, while saddling them with unnecessary costs. Another concern is that the approval of remdesivir, especially with such mixed evidence for its effectiveness, could undermine further research. Topol noted that with remdesivir now as the only fully approved standard of care, it becomes much more difficult to conduct studies on other therapies, since they now have to be compared to remdesivir, the new standard of care, as well as a placebo. That raises the cost and complexity of trials, delaying results. Such comparisons are worthwhile if the standard of care is effective, but it adds unnecessary complications if it’s not. It also makes it harder to recruit people for subsequent clinical trials of the drug to better validate its effectiveness. People may be more reluctant to sign up for a trial where they could get a placebo when they know they could get the actual drug. “The biggest, most serious problem is that we won’t get to the truth,” Topol said. It’s worth noting that remdesivir could still be a viable treatment for Covid-19, but the evidence presented so far is contradictory, and more investigation is needed to clarify its effectiveness. So then why did FDA go ahead with its approval? It’s hard to say, but Herschel Nachlis, a research assistant professor of government at Dartmouth College, suggested that the FDA approval might be a strategic move by the agency to deflect political pressure away from the all-important Covid-19 vaccination campaign. There is no evidence that the White House is interfering with the vaccine approval process directly, but President Trump has linked a vaccine to his election prospects and blamed the FDA for holding it back. The appearance that a Covid-19 vaccine was rushed to meet political needs could make people reluctant to get vaccinated, so regulators are keen to distance themselves from the 2020 election campaign. “If, in the short term, approving remdesivir gives the President a win and alleviates some pressure on the agency from the President about vaccines, that helps buy the FDA important time,” Nachlis said in an email. “It might be another case, like convalescent plasma, of giving up some ground in a battle to put yourself in the position to be able to win the broader war.” Whether Nachlis’s hypothesis is correct isn’t yet known. But what is clear is that the evidence on remdesivir’s effectiveness appears to be mixed, which is why it would have been helpful for the FDA to have held a public advisory committee meeting to discuss the evidence, a step it typically takes for full pharmaceutical approvals. Since it may be months before a vaccine for Covid-19 is available, treatments are still urgently needed — and other approaches are being studied. Trump, for example, also underwent a course of an experimental monoclonal antibody therapy from the company Regeneron when he was treated for Covid-19. There are now multiple clinical trials of these drugs underway, but now they have competition. Help keep Vox free for all Millions turn to Vox each month to understand what’s happening in the news, from the coronavirus crisis to a racial reckoning to what is, quite possibly, the most consequential presidential election of our lifetimes. Our mission has never been more vital than it is in this moment: to empower you through understanding. But our distinctive brand of explanatory journalism takes resources. Even when the economy and the news advertising market recovers, your support will be a critical part of sustaining our resource-intensive work. If you have already contributed, thank you. If you haven’t, please consider helping everyone make sense of an increasingly chaotic world: Contribute today from as little as $3.
2 h
vox.com
'I Voted for a Guy Named Trump' President Says in Florida Where Polling is Divided
President Trump has become one of more than 50 million Americans to cast their ballots early this year.
2 h
newsweek.com
US president says he voted for 'guy named Trump'
The US President said he voted "for a guy named Trump" after he cast his ballot in Florida on Saturday in early voting in the presidential elections.(Oct. 24)       
2 h
usatoday.com
Minnesota mail-in voting, early turnout shattering records
Minnesota voter turnout "shatters all records," State Secretary Steve Simon said. More than 1 million residents have voted by mail.
2 h
foxnews.com